Fig. 5

Least squares mean change from baseline in rPJPS in ORAL Start. Data represent total mTSS in five joint groups at A month 6 or B month 12 and C erosion and JSN scores at month 12, for patients receiving tofacitinib 5 or 10 mg BID or methotrexate. Data are based on a mixed model for repeated measures adjusted for age, geographic region, RA disease duration, disease activity (measured by DAS28-4(ESR)), and the baseline value of the endpoint. *P < 0.05; **P < 0.01; ***P < 0.001 tofacitinib 5 or 10 mg BID vs methotrexate. No multiplicity adjustments were made for statistical comparisons. ∆rPJPS, change from baseline in rPJPS; BID, twice daily; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; IP, interphalangeal; JSN, joint space narrowing (score); MCP, metacarpophalangeal; MTP, metatarsophalangeal; mTSS, Modified Total Sharp Score; N, number of patients assessed; PIP, proximal interphalangeal; RA, rheumatoid arthritis; rPJPS, radiographic paired joint pathology score; SE, standard error